Ginkgo Bioworks Holdings, Inc. WT
DNA-WT
New York Stock Exchange0.27
USD
-0.01
- -
Ginkgo Bioworks Holdings, Inc. WT
DNA-WT
(New York Stock Exchange)
Recent
price
0.27
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Ginkgo Bioworks Holdings, Inc. stands as a prominent biotechnology enterprise, specializing in a comprehensive platform for advanced cell programming and biosecurity initiatives. The company employs sophisticated genetic engineering techniques to develop bespoke microorganisms and cellular solutions for a wide array of sectors. Its core offering centers on an integrated platform comprising the Foundry, an automated facility dedicated to high-throughput biological research and development, and the Codebase, an expanding repository of biological designs and data that continually enhances engineering efficacy. Ginkgo Bioworks extends its services across diverse markets, including agriculture, food production, specialty chemicals, consumer goods, and pharmaceuticals, with the fundamental goal of simplifying biological engineering for transformative innovations. Their diverse portfolio encompasses the development of vaccines, enzymes, proteins, and small molecules, alongside specialized cell and gene therapy support. Additionally, it delivers crucial biosecurity infrastructure and solutions, enabling the prediction, detection, monitoring, and mitigation of biological threats for both governmental bodies and commercial entities. The firm's revenue generation strategy involves initial fees for research and development services, performance-based milestone payments, royalties or equity interests derived from successful product commercialization, and subscription-based access to its advanced technological capabilities. Recent corporate developments include the announcement of third-quarter 2025 financial results, as well as strategic collaborations such as contributing to an Illinois-led initiative for innovative oral health treatments and securing a project agreement through BARDA’s BioMaP-Consortium in late 2025. The company has also introduced a new in vitro ADME profiling service and successfully achieved significant cost reduction targets. Ginkgo Bioworks distinguishes itself through its scalable, AI-driven platform, designed to reduce research and development expenses and accelerate development timelines for its partners.